The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans

Hepatology

Volumn 30, Issue 1, 1999, Pages 14-20

  Kallien, Götz ^a   Lange, Kerstin ^a   Stange, Eduard F ^a   Scheibner, Jürgen ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PRAVASTATIN;

ADULT; ARTICLE; BILE SECRETION; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENTEROHEPATIC CIRCULATION; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MASS SPECTROMETRY; METABOLIC INHIBITION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ACETATES; ADULT; ANTICHOLESTEREMIC AGENTS; CARBON ISOTOPES; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GALLBLADDER; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINETICS; MALE; PLACEBOS; PRAVASTATIN;

EID: 0033002042     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300119     Document Type: Article

References (21)

1. Apstein MD, Carey MC. Pathogenesis of cholesterol gallstones: a parsimonious hypothesis. Eur J Clin Invest 1996;26:343-352.
2. Paumgartner G, Sauerbruch T. Gallstones: pathogenesis. Lancet 1991;338:1117-1121.
3. Scheibner J, Fuchs M, Hörmann E, Tauber G, Stange EF. Biliary cholesterol secretion and bile acid formation in the hamster: the role of newly synthesized cholesterol. J Lipid Res 1994;35:690-697.
4. Scheibner J, Fuchs M, Schiemann M, Tauber G, Hörmann E, Stange EF. Bile acid synthesis from newly synthesized vs. preformed cholesterol precursor pools in the rat. HEPATOLOGY 1993;17:1095-1102.
5. Turley SD, Dietschy JM. The contribution of newly synthesized cholesterol to biliary cholesterol in the rat. J Biol Chem 1981;256:2438-2446.
6. Turley SD, Spady DK, Dietschy JM. Alteration of the degree of biliary cholesterol saturation in the hamster and rat by manipulation of the pools of preformed and newly synthesized cholesterol. Gastroenterology 1983;84:253-264.
7. Schwartz CC, Berman M, Vlahcevic ZR, Halloran LG, Gregory DH, Swell L. Multicompartmental analysis of cholesterol metabolism in man. Characterization of the hepatic bile acid and biliary cholesterol precursor sites. J Clin Invest 1978;61:408-423.
8. Schwartz CC, Halloran LG, Vlahcevic ZR, Swell L, Gregory DH. Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science 1978;200:62-64.
9. Empen K, Lange K, Stange EF, Scheibner J. Newly synthesized cholesterol in human bile and plasma: quantification by mass isotopomer distribution analysis. Am J Physiol 1997;272:G367-G373.
10. Stahlberg D, Rudling M, Angelin B, Björkhem I, Forsell P, Nilsell K, Einarsson K. Hepatic cholesterol metabolism in human obesity. HEPATOLOGY 1997;25:1447-1450.
11. Ahmed HA, Jazrawi RP, Goggin PM, Dormandy J, Northfield TC. Intrahepatic biliary cholesterol and phospholipid transport in humans: effect of obesity and cholesterol cholelithiasis. J Lipid Res 1995;36:2562-2573.
12. Kern F Jr. Effects of dietary cholesterol on cholesterol and bile acid homeostasis in patients with cholesterol gallstones. J Clin Invest 1994;93:1186-1194.
13. Salen G, Nicolau G, Shefer S, Mosbach EH. Hepatic cholesterol metabolism in patients with gallstones. Gastroenterology 1975;69:676-684.
14. Ahlberg J, Angelin B, Einarsson K. Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment. J Lipid Res 1981;22:410-422.
15. Carulli N, De Leon MP, Zironi F, Pinetti A, Smerieri A, lori R, Loria P. Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short term feeding of chenodeoxycholic and ursodeoxycholic acid. J Lipid Res 1980;21:35-43.
16. Bennion LJ, Grundy SM. Effects of obesity and caloric intake on biliary lipid metabolism in man. J Clin Invest 1975;56:996-1011.
17. Reuben A, Qureshi Y, Murphy GM, Dowling RH. Effect of obesity and weight reduction on biliary cholesterol saturation and the response to chenodeoxycholic acid. Eur J Clin Invest 1985;16:133-142.
18. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. HEPATOLOGY 1988;8:1147-1150.
19. Logan GM, Duane WC. Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation. Gastroenterology 1990;98:1572-1576.
20. Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys 1996;325:242-248.
21. Watts GF, Naoumova RP, Kelly JM, Riches FM, Croft KD, Thompson GR. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 1997;273:E462-E470.